Kolon TissueGene, Inc. Logo

Kolon TissueGene, Inc.

Developing cell and gene therapies for orthopedic and degenerative disorders.

950160 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
9713 Key West Ave Suite 300, Rockville
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, disease-modifying allogeneic cell therapy for the treatment of knee osteoarthritis. This innovative therapy is designed to reduce pain, improve joint function, and potentially slow disease progression. Kolon TissueGene is advancing TG-C through late-stage clinical trials and exploring the application of its platform technology for other degenerative conditions, such as spinal diseases.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Kolon TissueGene, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-12 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 88.5 KB
2025-09-11 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 20.0 KB
2025-09-10 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 13.9 KB
2025-09-09 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 19.1 KB
2025-09-04 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 18.6 KB
2025-08-27 00:00
Legal Proceedings Report
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Korean 18.7 KB
2025-08-14 00:00
Capital/Financing Update
파생상품거래손실발생
Korean 7.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB

Automate Your Workflow. Get a real-time feed of all Kolon TissueGene, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Kolon TissueGene, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
PEPTONIC Medical AB Logo
Develops clinically proven self-care products for women's intimate health.
Sweden PMED
Develops sustained-release peptide medicines for chronic & neurodegenerative disorders.
South Korea 087010
Perseus Proteomics Inc. Logo
Develops antibody drugs for cancer, provides research support, and sells diagnostic reagents.
Japan 4882
PharmAbcine Inc. Logo
Develops antibody therapies for cancer, eye diseases, and vascular-related disorders.
South Korea 208340
Pharma Foods International Co., Ltd. Logo
Researches and sells functional ingredients and direct-to-consumer health & beauty products.
Japan 2929
Pharma Mar S.A. Logo
Develops and commercializes marine-derived oncology treatments for rare cancers.
Spain PHM
Pharmanutra Logo
Researches and markets nutritional supplements & medical devices for all ages.
Italy PHN
PHARMARESEARCH BIO Co., Ltd. Logo
A global biopharma firm creating regenerative medicine, pharmaceuticals, devices, and cosmetics.
South Korea 217950
PharmaResearch Co., Ltd. Logo
Develops regenerative medicine, devices & cosmetics using marine biotechnology.
South Korea 214450
PharmaSGP Holding SE Logo
Develops and markets leading natural OTC drugs for chronic conditions in the European market.
Germany PSG

Talk to a Data Expert

Have a question? We'll get back to you promptly.